Immunotherapy / PD-1 inhibitorFDA-approvedSecond-line
Opdivo
Generic name: nivolumab
How it works
Blocks the PD-1 receptor on immune cells, allowing them to recognize and attack cancer cells.
Cancer types
Lung Cancer— All patients
Efficacy
In clinical trials, patients with non-small cell lung cancer who received Opdivo had a response rate of approximately 20%.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing IL2 and Immunotherapy in Advanced Melanoma Patients | Melanoma | phase-2 | — | Source → |
| Testing New Treatments for Advanced Melanoma | Melanoma | phase-2 | — | Source → |
| Evaluating a New Combination Therapy for Advanced Colorectal Cancer | Colorectal Cancer | phase-2 | — | Source → |
| Testing Nivolumab with Standard Treatment for Colorectal Cancer with BRAF Mutation | Colorectal Cancer | phase-2 | — | Source → |
| Melanoma Treatment Trial Investigates Combination of NeoVax and Immunotherapies | Melanoma | phase-1 | — | Source → |
| Immunotherapy May Offer Better Survival for Lung Cancer Patients with Poor Health | Lung Cancer | phase-3 | Median overall survival was significantly longer with nivolumab: 29-weeks (95% CI: 11.3-46.7) versus 8-weeks (95% CI: 3.5-12.5; p<0.001) | Source → |
| Evaluating Nivolumab and Ipilimumab in Combination with Chemotherapy for Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Evaluating Nivolumab and Docetaxel for Advanced Lung Cancer | Lung Cancer | preclinical | — | Source → |
| Testing Combination Therapy for Advanced Breast Cancer and Solid Tumors | Breast Cancer | phase-1 | — | Source → |
| Preventing Mucosal Melanoma Return After Surgery | Melanoma | phase-2 | — | Source → |
| Testing New Treatments for Advanced Melanoma That Has Progressed | Melanoma | phase-3 | — | Source → |
| Testing a New Combination Treatment for Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Low-dose nivolumab shows promise in treating lung cancer | Lung Cancer | phase-2 | The estimated 2-year event-free survival rate was 56.1% (95% confidence interval [CI]: 38.3%-73.9%), and the 2-year disease-free survival rate was 66.6% (95% CI: 56.4%-86.8%). | Source → |
| Testing a New Treatment for Advanced Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Testing Nivolumab to Prevent Leukemia Relapse | Leukemia | phase-2 | — | Source → |
| Testing Nivolumab and Ipilimumab with Radiation in Advanced Rectal Cancer | Colorectal Cancer | phase-2 | — | Source → |
| Trial Tests Cancer Drugs in HIV Patients | Breast Cancer | phase-1 | — | Source → |
| Testing Immunotherapy After Surgery for High-Risk Melanoma | Melanoma | phase-3 | — | Source → |
| Testing Tocilizumab with Immunotherapy for Advanced Melanoma | Melanoma | phase-2 | — | Source → |
| Immunotherapy Shows Promise for Rare Ovarian and Cervical Cancers | Leukemia | phase-2 | The overall response rate was 9.38%, with two complete responses that are ongoing at >3 years and one partial response. | Source → |
| Nivolumab's Safety and Effectiveness in Chinese Lung Cancer Patients | Lung Cancer | observational | The median overall survival was 21.2 months. | Source → |
| B cells and genetic changes may predict response to cancer treatment | Ovarian Cancer | phase-2 | More than two passenger fusion genes were detected in six of the seven responders, whereas eight of the ten non-responders lacked fusion genes. | Source → |
| GRIm Score Predicts Response to Melanoma Treatment | Melanoma | observational | Patients with a low GRIm Score had significantly longer median progression-free survival (21.4 vs. 6.3 months, p = 0.003) and overall survival (26.5 vs. 7.2 months, p < 0.001). | Source → |
| Combining Immunotherapy for Advanced Anal Cancer | Colorectal Cancer | phase-2 | The median progression-free survival was 2.9 months for nivolumab and 3.7 months for nivolumab plus ipilimumab. | Source → |
| New Biomarker Predicts Outcomes for Lung Cancer Patients on Nivolumab | Lung Cancer | observational | Patients with GLR <70.76 achieved significantly longer OS (median 24.1 vs 9.6 months; p < 0.001) and PFS (9.7 vs 5.8 months; p < 0.001) compared with those with GLR ≥70.76. | Source → |
| Immunotherapy Response Predicted by Low Tumor Mutation Burden and PD-L1 Expression | Melanoma | observational | — | Source → |
| Combining TM5614 and Nivolumab to Treat Advanced Melanoma | Melanoma | phase-3 | — | Source → |
| Long-term remission in lung cancer patient treated with nivolumab | Lung Cancer | observational | The patient remained in continuous remission with a progression-free survival exceeding 82 months and an overall survival exceeding 84 months. | Source → |
| Rare Side Effect of Cancer Treatment in Older Patient | Melanoma | observational | — | Source → |
| Cost-Effectiveness of Lung Cancer Treatment Questioned | Lung Cancer | phase-3 | Nivolumab plus bevacizumab and chemotherapy yielded an additional 0.90 QALYs with the marginal cost of $231,948.33. | Source → |
| New Study Explores Using Nivolumab to Treat Malignant Ascites | Pancreatic Cancer | phase-2 | Seven patients (77.8%) showed a clinical response. | Source → |
| Melanoma Study Examines Vaccine Combination with Immunotherapy | Melanoma | phase-2 | Objective response rates were 59.7% and 59.2% in the two treatment arms. | Source → |
| Combining Nivolumab with Chemotherapy for Advanced Ovarian Cancer | Ovarian Cancer | phase-2 | Fifteen of the 20 evaluable patients had complete gross resection at ICS, and 7 of 20 achieved an optimal pathologic chemotherapy response score of 3. | Source → |
| Immune therapy may trigger severe colitis in some patients | Melanoma | observational | — | Source → |
| Combination Treatment Shows Promise for Rare Gynecological Cancers | Ovarian Cancer | phase-2 | The overall objective response rate was 54% (95% CI, 35-71), with 3 (12%) complete responses and 12 (42%) partial responses. | Source → |
| Study Examines Combination Therapy for Advanced Liver Cancer | Colorectal Cancer | phase-2 | — | Source → |
| Cost-effectiveness of dual immunotherapy for lung cancer | Lung Cancer | phase-3 | Nivolumab plus ipilimumab provided an incremental gain of 1.11 and 0.96 QALYs over chemotherapy in the USA and China, respectively. | Source → |
| Comparing Two Ways to Give Cancer Treatment | Melanoma | phase-2 | — | Source → |
| Long-term Survival and Response to Immunotherapy in Melanoma Patients | Melanoma | phase-2 | At 4 years from the start of treatment, 80% of patients remained event-free, including 95% of patients who achieved a major pathologic response. | Source → |
| Combining RP1 and Nivolumab May Help Some Melanoma Patients | Melanoma | phase-2 | The confirmed objective response rate was 32.9% (95% CI, 25.2% to 41.3%; 15.0% complete response). | Source → |
| TIL Therapy for Melanoma Patients May Benefit from IFNα Support | Melanoma | phase-2 | Disease control was obtained in 11.1% of the patients treated without IFNα and in 41.7% of the patients treated with IFNα. | Source → |
| Rare Side Effect of Cancer Treatment: Tongue Discoloration | Ovarian Cancer | observational | — | Source → |
| Combination Therapy Improves Survival in Advanced Melanoma Patients | Melanoma | preclinical | The 4-year progression-free survival rate was 30.6% for nivolumab plus relatlimab versus 23.6% for nivolumab alone. | Source → |
| Combination Therapy Shows Promise for Metastatic Uveal Melanoma | Melanoma | observational | — | Source → |
| Color Vision Loss in Melanoma Patient Treated with Nivolumab-Relatlimab | Melanoma | observational | — | Source → |
| Nivolumab Treatment in Melanoma Patients: Immune and Nutritional Status Linked to Survival | Melanoma | observational | Patients with high HALP scores had significantly longer progression-free survival (PFS: median 5.8 vs 3.1 months) and overall survival (OS: median 54.9 vs 14.4 months) compared to those with low HALP scores. | Source → |
| Combining Telaglenastat and Nivolumab in Cancer Treatment | Melanoma | phase-1/2 | The overall response rate was 8.4% in the response-assessable analysis set. | Source → |
| Rare Side Effects of Cancer Treatment | Melanoma | observational | — | Source → |
| Nivolumab Effectiveness in Non-Small Cell Lung Cancer | Lung Cancer | observational | The 36-month OS rate was 19.7% (95% confidence interval [CI] 17.5-22.0); the 12-month investigator-assessed best ORR in the overall population was 20.4%. | Source → |
| Inflammatory Markers and Metastases Predict Nivolumab Response in Lung Cancer | Lung Cancer | observational | The median overall survival was 21.2 months (95% CI: 17.4-25.0). | Source → |
| Brazilian Study Examines Cost of New Melanoma Treatments | Melanoma | observational | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.